BACKGROUND/ OBJECTIVES: Combination hepatic artery infusion (HAI) and systemic (SYS) chemotherapy for unresectable CRLM results in high tumor-response rates. This study represents an update of long-term survival and conversion to resectability in patients with unresectable CRLM treated with HAI and SYS chemotherapy in a phase II study. METHOD: The primary endpoint was complete resection. Multivariate and landmark analysis assessed the effect of complete resection on progression-free (PFS) and overall survival (OS). RESULTS: From 2007 to 2012, 64 patients with median of 13 tumors were enrolled; 67% had prior chemotherapy. 33 patients (52%) were converted to resection. Median follow-up among survivors was 81 months. Median PFS and OS were 13 and 38 months, respectively, with 5-year-OS of 36%. Chemotherapy-naïve patients had 5-year-OS of 51%. Conversion to resection was the only independent factor prognostic of improved PFS and OS. Nine of 64 patients (14%) are NED (five since initial resection, three after resection of recurrent disease, one from chemotherapy alone) at median follow-up of 86 months from treatment initiation, and 72 months from last operative intervention. CONCLUSION: Combination HAI and SYS is an effective therapy for high-volume unresectable CRLM, resulting in a high rate of resection, long-term survival, and the potential for cure.
BACKGROUND/ OBJECTIVES: Combination hepatic artery infusion (HAI) and systemic (SYS) chemotherapy for unresectable CRLM results in high tumor-response rates. This study represents an update of long-term survival and conversion to resectability in patients with unresectable CRLM treated with HAI and SYS chemotherapy in a phase II study. METHOD: The primary endpoint was complete resection. Multivariate and landmark analysis assessed the effect of complete resection on progression-free (PFS) and overall survival (OS). RESULTS: From 2007 to 2012, 64 patients with median of 13 tumors were enrolled; 67% had prior chemotherapy. 33 patients (52%) were converted to resection. Median follow-up among survivors was 81 months. Median PFS and OS were 13 and 38 months, respectively, with 5-year-OS of 36%. Chemotherapy-naïve patients had 5-year-OS of 51%. Conversion to resection was the only independent factor prognostic of improved PFS and OS. Nine of 64 patients (14%) are NED (five since initial resection, three after resection of recurrent disease, one from chemotherapy alone) at median follow-up of 86 months from treatment initiation, and 72 months from last operative intervention. CONCLUSION: Combination HAI and SYS is an effective therapy for high-volume unresectable CRLM, resulting in a high rate of resection, long-term survival, and the potential for cure.
Authors: Mehrdad Nikfarjam; Serene Shereef; Eric T Kimchi; Niraj J Gusani; Yixing Jiang; Diego M Avella; Rickhesvar P Mahraj; Kevin F Staveley-O'Carroll Journal: Ann Surg Oncol Date: 2008-11-27 Impact factor: 5.344
Authors: C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: M Narita; E Oussoultzoglou; D Jaeck; P Fuchschuber; E Rosso; P Pessaux; E Marzano; P Bachellier Journal: Br J Surg Date: 2011-06-28 Impact factor: 6.939
Authors: Nancy E Kemeny; Fidel D Huitzil Melendez; Marinela Capanu; Philip B Paty; Yuman Fong; Lawrence H Schwartz; William R Jarnagin; Dina Patel; Michael D'Angelica Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Hordur M Kolbeinsson; Randa Preihs; Alexandra Bengel; Sreenivasa Chandana; M Mura Assifi; Mathew H Chung; G Paul Wright Journal: J Gastrointest Oncol Date: 2022-02
Authors: Jashodeep Datta; Raja R Narayan; Debra A Goldman; Walid K Chatila; Mithat Gonen; James Strong; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; William R Jarnagin; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica Journal: Ann Surg Date: 2020-11-17 Impact factor: 13.787
Authors: Hala Muaddi; Michael D'Angelica; Jason T Wiseman; Mary Dillhoff; Nicholas Latchana; Rachel Roke; Yoo-Joung Ko; Darren Carpizo; Kristen Spencer; Ryan C Fields; Gregory Williams; Federico Aucejo; Lou-Anne Acevedo-Moreno; Kevin G Billingsley; Brett S Walker; Skye C Mayo; Paul J Karanicolas Journal: J Surg Oncol Date: 2020-10-23 Impact factor: 3.454